Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Synthesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112159831B reveals cost-effective enzymatic NMN synthesis. Discover supply chain advantages and high-purity manufacturing capabilities for global buyers.
Patent CN110452920A reveals high-efficiency enzymatic route for L-phenylglycine, offering supply chain stability and cost reduction for pharmaceutical intermediates manufacturing.
Patent CN118638174A reveals a plant-based UDCA synthesis route. Achieve 99.91% purity with reduced viral risk and scalable enzymatic steps for reliable supply.
Patent CN119119158A reveals a novel plant-derived route for ursodeoxycholic acid. Achieve high purity and cost reduction in API manufacturing with scalable bio-hybrid synthesis.
Patent CN110835639B reveals a high-efficiency enzymatic route for producing chiral tetrahydroisoquinoline intermediates with superior stereoselectivity and scalable manufacturing potential.
Novel chemo-enzymatic route for diabetes drug intermediate offers high purity and scalable manufacturing solutions for global pharmaceutical supply chains efficiently.
Patent CN108300744A reveals enzymatic synthesis for high purity D-heterocyclic amino acids. This technology reduces cost and improves supply chain reliability for global pharmaceutical buyers seeking scalable intermediates.
Patent CN118791350B reveals enzymatic synthesis of novel antibacterial diterpenoids. Offers green manufacturing and supply chain reliability for pharmaceutical intermediates.
Patent CN108587991A reveals novel aminotransferase and isomerase pairs for L-allo-Ile production. Discover green enzymatic methods for high-purity pharmaceutical intermediates and cost reduction.
Novel enzymatic route for high-purity peptide intermediates. Reduces cost and improves scalability for pharmaceutical manufacturing processes globally.
Novel chemo-enzymatic route for Eluxadoline intermediate. High yield, scalable, cost-effective pharmaceutical intermediates manufacturing for global supply chains.
Patent CN119552837B reveals high-efficiency enzymatic route for Brivaracetam intermediates, offering superior purity and scalable manufacturing solutions for global supply chains.
Patent CN115521961A reveals high-efficiency alpha-amino acid ester acyltransferase for L-Alanyl-L-Glutamine production, offering superior conversion rates and cost-effective manufacturing solutions.
Patent CN119776462A reveals one-pot enzymatic synthesis for pseudouridine. High purity and yield offer significant supply chain and cost advantages for mRNA manufacturers.
Novel chemo-enzymatic route for pseudouridine offers high purity and scalable production for mRNA vaccine manufacturers seeking reliable supply.
Patent CN114196715A details a novel chemo-enzymatic method for pseudouridine using engineered glycosidase mutants, offering high conversion and simplified purification for mRNA vaccine supply chains.
Patent CN114507650B reveals a mutant enzyme boosting yield and purity for Clopidogrel intermediates, ensuring stable supply chains and reduced manufacturing costs for global buyers.
Patent CN104152498A details high-efficiency enzymatic synthesis for alpha-ketoglutaric acid, offering superior purity and cost-effective supply chain solutions for global buyers.
Patent CN109851658B reveals one-step L-carnosine synthesis reducing cost and improving supply chain reliability for pharmaceutical intermediates.
Patent CN107721853A reveals enzymatic synthesis for latamoxef side chain. High purity, green process, cost reduction in pharma intermediate manufacturing.